DNA biodots based targeted theranostic nanomedicine for the imaging and treatment of non-small cell lung cancer

摘要

The light absorption and emission characteristics of DNA biodots (DNA-BD), along with biocompatibility, give them a high potential for use in various medical applications, particularly in diagnostic purpose. DNA, under high pressure and temperature, condenses W form luminescent biodots. The objective of this research is lo develop DNA-biodols (BD) loaded and celuximab conjugated targeted theranostic liposomes of effiposide for lung cancer imaging and therapy. Theranostic liposomes were prepared by using the solvent injection method and characterized for their particle size, polydispersity, zeta potential, encapsulation efficiency, and pHdependent in-vitro release, SEM, TEM AFM, EDX, and XRD. The t50% (time at which 50% of the drug releases from the preparation) of the tot mulations was pH-dependent, with a significant increase in the release at lower pH (55). To kill A549 adenocarcinoma cells, the etoposide (control) required significantly (p < 0.05) higher drug concentrations in comparison to non-targeted and; the non-targeted formulation required more concentrations in comparison to targeted liposomes. The in-vivo results demonstrated that CTX-TPGS decorated theranostic I iposomes could be a promising carrier for lung theranostics due to their nano-size and selectivity towards EGER overexpressed cells which provided an improved NSCLC targeted delivery of ETP in comparison to the non-targeted and control formulations. (C) 2020 Elsevier B.V. All rights reserved.